Both the Food and Drug Administration (FDA) and Biogen, Inc. have prepared pre-recorded presentations for the November 6, 2020, Peripheral and Central Nervous System Drugs Advisory Committee meeting. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day**.

The recordings of the presentations can be found at the following addresses:

**FDA Presentations (listed in viewing order):**

1. Clinical Overview of Efficacy: Aducanumab for the Treatment of Alzheimer’s Disease by Kevin M. Krudys, PhD; Division of Neurology 1 (1 of 3) - [https://collaboration.fda.gov/p01bfo7hfeka](https://collaboration.fda.gov/p01bfo7hfeka)
2. Clinical Overview of Safety: Aducanumab for the Treatment of Alzheimer’s Disease by Natalie Branan, MD and Brian Trummer, MD, PhD; Division of Neurology 1 (2 of 3) - [https://collaboration.fda.gov/puu0x7miwjmi](https://collaboration.fda.gov/puu0x7miwjmi)
3. BLA 761178 Statistical Review: Aducanumab in Alzheimer’s by Tristan Massie, PhD; Office of Biostatistics (3 of 3) - [https://collaboration.fda.gov/pradgevcxis7](https://collaboration.fda.gov/pradgevcxis7)

**Biogen, Inc. Presentations (listed in viewing order):**

1. Introduction: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (1 of 7) - [https://collaboration.fda.gov/py8yfqrtjef0](https://collaboration.fda.gov/py8yfqrtjef0)
2. Unmet Need: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (2 of 7) - [https://collaboration.fda.gov/p3btb1z4k2r](https://collaboration.fda.gov/p3btb1z4k2r)
3. Clinical Development: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (3 of 7) - [https://collaboration.fda.gov/pm67ry34ml2i](https://collaboration.fda.gov/pm67ry34ml2i)
4. Efficacy: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (4 of 7) - [https://collaboration.fda.gov/p4w1qpr1rw6y](https://collaboration.fda.gov/p4w1qpr1rw6y)
5. Study Investigation: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (5 of 7) - [https://collaboration.fda.gov/pwb4jutjsndq](https://collaboration.fda.gov/pwb4jutjsndq)
6. Safety: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (6 of 7) - [https://collaboration.fda.gov/pf3eij6ty9ws](https://collaboration.fda.gov/pf3eij6ty9ws)
7. Clinical Perspective: Aducanumab for the treatment of Alzheimer’s Disease by Biogen (7 of 7) - [https://collaboration.fda.gov/pd0qptnl06bb](https://collaboration.fda.gov/pd0qptnl06bb)

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at: [https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/2020-meeting-materials-peripheral-and-central-nervous-system-drugs-advisory-committee](https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/2020-meeting-materials-peripheral-and-central-nervous-system-drugs-advisory-committee)